Description of Gyre Therapeutics Inc's Business Segments

The Company operates two distinct reportable segments, defined as components for which separate financial information is available and regularly reviewed by the Chief Operating Decision Maker (CODM) to allocate resources and assess performance. Segment profit or loss is measured by consolidated net income, which the CODM uses to evaluate income from segment assets, decide on profit reinvestment, and monitor budget versus actual results. The CODM group comprises the Executive Chairman of Gyre’s Board of Directors, who also serves as Gyre’s Interim Chief Executive Officer, and Gyre’s Chief Operating Officer, who also serves as Gyre Pharmaceuticals’ General Manager.

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Composition of Gyre Therapeutics Inc Revenues by Segments


Product	168.1 %	of total Revenue
Contiva	5.95 %	of total Revenue
Etorel	3.19 %	of total Revenue
Other Products Product Sales	0.11 %	of total Revenue
Collaborations	6.59 %	of total Revenue
Pharmaceutical Products	177.29 %	of total Revenue
Gyre Pharmaceuticals	177.34 %	of total Revenue
Gyre	6.59 %	of total Revenue

Q2 three months ended (Jun 30 2026)
Revenues by Business Segments	Revenues (in millions $)	% (of total Revenues)
Product	48.93	168.1 %
Contiva	1.73	5.95 %
Etorel	0.93	3.19 %
Other Products Product Sales	0.03	0.11 %
Collaborations	1.92	6.59 %
Pharmaceutical Products	51.60	177.29 %
Gyre Pharmaceuticals	51.62	177.34 %
Gyre	1.92	6.59 %
Total	29.11	100 %

Q2 three months ended (Jun 30 2026)
Revenue Growth rates by Segment	Y/Y Revenue %	Q/Q Revenue %
Product	-	-
Contiva	-	-
Etorel	-	-
Other Products Product Sales	-	99900 %
Collaborations	-	-
Pharmaceutical Products	-	-
Gyre Pharmaceuticals	92.81 %	129.21 %
Gyre	-	-
Total	8.72 %	29.25 %

Q2 three months ended (Jun 30 2026)
Income by Business Segments	Income (in millions $)	% (Profit Margin)
Total	-14.27	-

Q2 three months ended (Jun 30 2026)
Income Growth rates by Segment	Y/Y Income %	Q/Q Income %
Total	-	-

Annual Report on Gyre Therapeutics Inc Divisions, Sales by Country


Contiva	4.73 %	of total Revenue
Etorel	3.96 %	of total Revenue
Gyre Pharmaceuticals	100 %	of total Revenue
ETUARY	91.04 %	of total Revenue
Other Products	0.27 %	of total Revenue

Twelve months ended 2025
GYRE s Annual Revenue by Geography and Business Segments	Sales (in millions $)	% (of total Sales)
Contiva	5.52	4.73 %
Etorel	4.62	3.96 %
Gyre Pharmaceuticals	116.59	100 %
Total	116.59	100 %
ETUARY	106.14	91.04 %
Other Products	0.31	0.27 %

Twelve months ended 2025
GYRE s Annual Income by Country and Business Segments	Income (in millions $)	% (Profit Margin)
Gyre Pharmaceuticals	19.99	17.15 %
Total	9.88	8.47 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments	% Y/Y Sales Growth	% Y/Y Income Growth
Gyre Pharmaceuticals	10.24 %	-9.21 %
Total	10.24 %	-44.8 %
ETUARY	1.07 %	-
Sales of Pharmaceutical Products	-	-
Other Products	-58.29 %	-

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.